Neurology, Neuropsychiatry, Psychosomatics

Advanced search

The etiology, manifestations, and therapy of chronic cerebrovascular diseases

Full Text:


The paper presents the current etiopathogenetic classification of chronic cerebrovascular diseases (CVD) and discusses the role of hypertension, cerebral amyloid angiopathy, and genetically determined syndromes in the development of this pathological condition. It gives recommendations for the neuroradiological diagnosis of chronic CVD in accordance with the international standards. The paper discusses the clinical manifestations of chronic CVD, primarily vascular cognitive impairment. It discusses international guidelines for the examination and treatment of patients with chronic CVD, as well as the rules for stroke prevention in this patient cohort. The possibilities of pathogenetically based therapy in decreasing the severity of vascular cognitive impairment in the presence of chronic CVD are also highlighted.

About the Authors

A. G. Gogoleva
N.V. Sklifosovsky Institute of Clinical Medicine I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery

11, Rossolimo St., Build. 1, Moscow 119021

V. V. Zakharov
N.V. Sklifosovsky Institute of Clinical Medicine I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Vladimir V. Zakharov

Department of Nervous System Diseases and Neurosurgery

11, Rossolimo St., Build. 1, Moscow 119021


1. Parfenov VA. Diagnosis and treatment of chronic cerebrovascular disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(3):4-9. doi: 10.14412/2074-2711-2016-3-4-9 (In Russ.).

2. Yesin RG, Yesin OR, Khayrullin IKh. Discirculatory encephalopathy and small vessel disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116(8):109-15 (In Russ.).

3. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007 Jul;6(7):611-9. doi: 10.1016/S1474-4422(07)70170-9

4. Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med. 2007 Nov 1;357(18):1821-8. doi: 10.1056/NEJMoa070972

5. Charidimou A, Pantoni L, Love S. The concept of sporadic cerebral small vessel disease: A road map on key definitions and current concepts. Int J Stroke. 2016 Jan;11(1):6-18. doi: 10.1177/1747493015607485

6. Levin OS. Distsirkulyatorny encephalopathy: anachronism or clinical reality? Sovremennaya terapiya v psikhiatrii i nevrologii. 2012;(3):40-6 (In Russ.).

7. Inzitari D, Simoni M, Pracucci G, et al, for the LADIS study group. Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch Intern Med. 2007 Jan 8;167(1):81-8. doi: 10.1001/archinte.167.1.81

8. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010 Jul;9(7):689-701. doi: 10.1016/S1474-4422(10)70104-6

9. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013 May;12(5):483-97. doi: 10.1016/S1474-4422(13)70060-7

10. Wardlaw JM, Sandercock PAG, Dennis MS, Starr J. Is breakdown of the bloodbrain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke. 2003 Mar;34(3):806-12. doi: 10.1161/01.STR.0000058480.77236.B3. Epub 2003 Feb 27.

11. Fernando MS, Simpson JE, Matthews F, et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke. 2006;37:1391-8. doi: 10.1161/01.STR.0000221308.94473.14

12. Rosenberg GA, Wallin A, Wardlaw JM, et al. Consensus statement for diagnosis of subcortical small vessel disease. J Cereb Blood Flow Metab. 2016 Jan;36(1):6-25. doi: 10.1038/jcbfm.2015.172

13. Arba F, Leigh R, Inzitari D, et al. Blood brain barrier leakage increases with small vessel disease in acute ischemic stroke. Neurology. 2017 Nov 21;89(21):2143-50. doi: 10.1212/WNL.0000000000004677. Epub 2017 Oct 25.

14. Akoudad S, Wolters FJ, Viswanathan A, et al. Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurol. 2016 Aug 1;73(8):934-43. doi: 10.1001/jamaneurol.2016.101

15. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993 Sep;43(9):1683-9. doi: 10.1212/wnl.43.9.1683

16. Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc. 2015 Jun 23;4(6):001140. doi: 10.1161/JAHA.114.001140

17. Greenberg SM, Vernooij MW, Cordonnier C, et al; Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009 Feb;8(2):165-74. doi: 10.1016/S1474-4422(09)70013-4

18. Moreau F, Patel S, Lauzon ML, et al. Cavitation after acute symptomatic lacunar stroke depends on time, location, and MRI sequence. Stroke. 2012 Jul;43(7):1837-42. doi: 10.1161/STROKEAHA.111.647859

19. De Jong G, Kessels F, Lodder J. Two types of lacunar infarcts: further arguments from a study on prognosis. Stroke. 2002 Aug;33(8):2072-6. doi: 10.1161/01.str.0000022807.06923.a3

20. Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke. 2010 Oct;41(10 Suppl):S103-6. doi: 10.1161/STROKEAHA.110.595181

21. Gregoire SM, Chaudhary UJ, Brown MM, et al. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology. 2009 Nov 24;73(21):1759-66. doi: 10.1212/WNL.0b013e3181c34a7d

22. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001 Feb 27;56(4):537-9. doi: 10.1212/wnl.56.4.537

23. Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurotherapeutics. 2007 Jul;4(3):316-29. doi: 10.1016/j.nurt.2007.05.011

24. Maillard P, Fletcher E, Harvey D, et al. White matter hyperintensity penumbra. Stroke 2011 Jul;42(7):1917-22. doi: 10.1161/STROKEAHA.110.609768. Epub 2011 Jun 2.

25. Evans TE, O'Sullivan MJ, de Groot M, et al. White matter microstructure improves stroke risk prediction in the general population. Stroke. 2016 Nov;47(11):2756-62. doi: 10.1161/STROKEAHA.116.014651. Epub 2016 Oct 4.

26. Yue NC, Longstreth Jr WT, Elster AD, et al. Clinically serious abnormalities found incidentally at MR imaging of the brain: data from the Cardiovascular Health Study. Radiology. 1997 Jan;202(1):41-6. doi: 10.1148/radiology.202.1.8988190

27. Das RR, Seshadri S, Beiser AS, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham Offspring Study. Stroke. 2008 Nov;39(11):2929-35. doi: 10.1161/STROKEAHA.108.516575. Epub 2008 Jun 26.

28. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med. 2014 Jul 9;12:119. doi: 10.1186/s12916-014-0119-0

29. Vermeer SE, Koudstaal PJ, Oudkerk M, et al. Prevalence and risk factors of silent brain infarcts in the population based Rotterdam Scan Study. Stroke. 2002 Jan;33(1):21-5. doi: 10.1161/hs0102.101629

30. Mosley TH Jr, Knopman DS, Catellier DJ, et al. Cerebral MRI findings and cognitive functioning: the Atherosclerosis Risk in Communities study. Neurology. 2005 Jun 28;64(12):2056-62. doi: 10.1212/01.WNL.0000165985.97397.88

31. Jorm AF, Anstey KJ, Christensen H, et al. MRI hyperintensities and depressive symptoms in a community sample of individuals 60–64 years old. Am J Psychiatry. 2005 Apr;162(4):699-705. doi: 10.1176/appi.ajp.162.4.699

32. Romero JR, Preis SR, Beiser A, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. Stroke. 2014 May;45(5):1492-4. doi: 10.1161/STROKEAHA.114.004130. Epub 2014 Apr 8.

33. Vemuri P, Lesnick TG, Przybelski SA, et al. (2015). Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain. 2015 Mar;138(Pt 3):761- 71. doi: 10.1093/brain/awu393. Epub 2015 Jan 15.

34. Knopman DS, Griswold ME, Lirette ST, et al. Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study. Stroke. 2015;46:433-40. doi: 10.1161/STROKEAHA.114.007847

35. Ding J, Sigurdsson S, Jonsson PV, et al. Large perivascular spaces visible on magnetic resonance imaging, cerebral small vessel disease progression, and risk of dementia: the age, gene/environment susceptibility – Reykjavik study. JAMA Neurol. 2017;74:1105-112. doi: 10.1001/jamaneurol.2017.1397

36. Paradise M, Seruga A, Crawford JD, et al. The relationship of cerebral microbleeds to cognition and incident dementia in non-demented older individuals. Brain Imaging Behav. 2019 Jun;13(3):750-61. doi: 10.1007/s11682-018-9883-3

37. Caunca MR, de Leon-Benedetti A, Latour L, et al. Neuroimaging of Cerebral Small Vessel Disease and Age-Related Cognitive Changes. Front. Aging Neurosci. 2019 Jun 27;11:145. doi: 10.3389/fnagi.2019.00145. eCollection 2019.

38. Arvanitakis Z, Fleischman DA, Arfanakis K, et al. Association of white matter hyperintensities and gray matter volume with cognition in older individuals without cognitive impairment. Brain Struct Funct. 2016;221:2135-46. doi: 10.1007/s00429-015-1034-7

39. Neverovsky DV, Sluchevskaya SF, Parfenov VA. Differential diagnosis of dyscirculatory encephalopathy in outpatient practice. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2):38-42. doi: 10.14412/2074-2711-2013-2411 (In Russ.).

40. Vakhnina NV. Vascular cognitive impairment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(1):74-9. doi: 10.14412/2074-2711-2014-1-74-79 (In Russ.).

41. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnyye rasstroystva [Cognitive Disorders]. Moscow: Remedium; 2015. 192 p. (In Russ.).

42. Smith EE, Saposnik G, Biessels GJ, et al. Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48:e44-e71. doi: 10.1161/STR.0000000000000116

43. Meschia JF, Bushnell C, Boden-Albala B, et al; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:3754-832. doi: 10.1161/STR.0000000000000046

44. Jauch EC, Saver JL, Adams HP Jr, et al; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947. doi: 10.1161/STR.0b013e318284056a

45. Kilarski LL, Rutten-Jacobs LCA, Bevan S, et al; UK Young Lacunar Stroke DNA Study. Prevalence of CADASIL and Fabry disease in a cohort of MRI defined younger onset lacunar stroke. PLoS One. 2015 Aug 25;10(8):e0136352. doi: 10.1371/journal.pone.0136352. eCollection 2015.

46. Bernick C, Kuller L, Dulberg C, et al; Cardiovascular Health Study Collaborative Reseach Group. Silent MRI infarcts and the risk of future stroke: the Cardiovascular Health Study. Neurology. 2001;57:1222-9. doi: 10.1212/WNL.57.7.1222

47. Duering M, Righart R, Csanadi E, et al. Incident subcortical infarcts induce focal thinning in connected cortical regions. Neurology. 2012 Nov 13;79(20):2025-8. doi: 10.1212/WNL.0b013e3182749f39. Epub 2012 Oct 10.

48. Parfenov VA, Ostroumova TM, Ostroumova OD, et al. Cognitive functions, emotional status, MRI measurements in treatment-naive middle-aged patients with uncomplicated essential arterial hypertension. Zhurnal nevrologii i psikhiatrii. 2018;(8):23-32 (In Russ.).

49. Kernan WN, Ovbiagele B, Black HR, et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association / American Stroke Association [published correction appears in Stroke. 2015;46:e54]. Stroke. 2014;45:2160-236. doi: 10.1161/STR.0000000000000024

50. Rossiyskoy kardiologicheskoye obshchestvo. Arterial'naya gipertenziya u vzroslykh: klinicheskiye rekomendatsii [Russian Society of Cardiology. Arterial hypertension in adults: clinical guidelines]. Available from: (In Russ.).

51. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.

52. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al; on behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581-641. doi: 10.1161/STR.0000000000000086

53. Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the Evaluation of Vascular Care in Alzheimer's Disease (EVA) study. Stroke. 2010 Mar;41(3):554-6. doi: 10.1161/STROKEAHA.109.571281. Epub 2010 Jan 7.

54. Balakumar P, Nyo YH, Renushia R, et al. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res. 2014 Sep;87:144-50. doi: 10.1016/j.phrs.2014.05.008. Epub 2014 May 24.

55. Cardiovascular prevention 2017. Russian national guidelines. Rossiyskiy kardiologicheskiy zhurnal. 2018;(6):7-122 (In Russ.).

56. Ciacciarelli M, Zerbinati C, Violi F. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem. 2015;15(9):822-9. doi: 10.2174/1568026615666150220111942

57. Chakrabarti S, Blair P, Wu C, Freedman JE. Redox state of dipyridamole is a critical determinant for its beneficial antioxidant and antiinflammatory effects. J Cardiovasc Pharmacol. 2007 Oct;50(4):449-57. doi: 10.1097/FJC.0b013e31813542db

58. Eisert WG. Dipyridamole in antithrombotic treatment. Adv Cardiol. 2012;47:78-86. doi: 10.1159/000338053. Epub 2012 Aug 9.

59. Vorob'yeva OV. The pleiotropic effects of dipyridamole: clinical perspectives. Effektivnaya farmakoterapiya. Nevrologiya. 2016;3(25):15-8 (In Russ.).

60. Putilina MV. Strategies for early diagnosis and treatment of small vessel disease in the brain. Consilium Medicum. 2018;20(9):22-9 (In Russ.).

61. Tanyashyan MM, Domashenko MA. The use of curantile in chronic cerebrovascular diseases. Atmosfera. Nervnyye bolezni. 2005;(3):8-11 (In Russ.).

62. Tanyashyan MM, Domashenko MA. Dipyridamole in the complex therapy of chronic cerebrovascular diseases. Nervnyye bolezni. 2012;(3):27-30 (In Russ.).


For citations:

Gogoleva A.G., Zakharov V.V. The etiology, manifestations, and therapy of chronic cerebrovascular diseases. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):84-91. (In Russ.)

Views: 441

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)